Nucleotide aptamers—short, highly specific oligonucleotide or ligands—are now recognized as highly promising molecular agents for both measuring and targeting key AD biomarkers, with the most notorious being amyloid-beta (Aβ), tau protein, and disease-associated microRNAs (miRNAs). Here, MAPT is linked to Alzheimer disease.